虚拟筛选
调节器
广告
癌症免疫疗法
造血
化学
计算生物学
生物
细胞生物学
癌症研究
计算机科学
免疫疗法
生物化学
药物发现
癌症
体外
干细胞
遗传学
基因
作者
Dazhi Feng,Bo Liu,Zhiwei Chen,Jinyi Xu,Meiyu Geng,Wenhu Duan,Jing Ai,Hefeng Zhang
标识
DOI:10.1080/07391102.2024.2301754
摘要
Hematopoietic progenitor kinase 1 (HPK1) is a key negative regulator of T-cell receptor (TCR) signaling and a promising target for cancer immunotherapy. The development of novel HPK1 inhibitors is challenging yet promising. In this study, we used a combination of machine learning (ML)-based virtual screening and free energy perturbation (FEP) calculations to identify novel HPK1 inhibitors. ML-based screening yielded 10 potent HPK1 inhibitors (IC50 < 1 μM). The FEP-guided modification of the in-house false-positive hit, DW21302, revealed that a single key atom change could trigger activity cliffs. The resulting DW21302-A was a potent HPK1 inhibitor (IC50 = 2.1 nM) and potently inhibited cellular HPK1 signaling and enhanced T-cell function. Molecular dynamics (MD) simulations and ADME predictions confirmed DW21302-A as candidate compound. This study provides new strategies and chemical scaffolds for HPK1 inhibitor development.Communicated by Ramaswamy H. Sarma.
科研通智能强力驱动
Strongly Powered by AbleSci AI